Cardiologists Are Begging People To Stop ‘Leaning Too Heavily' on This One Daily Metric
Cardiologists Are Begging People To Stop 'Leaning Too Heavily' on This One Daily Metric originally appeared on Parade.
It's really easy to fall into TikTok rabbit holes, especially when it comes to your health, and heart health is no exception. Whether it's dangerous diet culture and weight loss discourse, supplement shilling or anti-vaccine messaging, it's easy to feel anxious that you aren't doing enough to stay healthy when you're scrolling.Is there yet another thing you should be doing to track your health, or is the latest TikTok wellness trend just a sales tactic to get you to buy a new device or to download another app that may use your data in potentially questionable ways? Below, cardiologists weigh in on the truth about a heart health metric, called , that influencers are insisting you need to measure—you know, along with everything else you're juggling just to exist in this timeline.Just remember: No one knows more about your actual health and what your body needs than you and your doctor, so check with your physician before implementing any changes one way or the other.🩺SIGN UP for tips to stay healthy & fit with the top moves, clean eats, health trends & more delivered right to your inbox twice a week💊
"Heart rate variability, or HRV, is the variation in time between each heartbeat," , cardiologist and vice president of medical affairs at Hello Heart, tells Parade. "It reflects how well your body can adapt to stress, rest and recovery. A higher HRV generally points to better cardiovascular fitness and resilience.""If your heart rate is 60 beats per minute, your heart doesn't beat exactly once per second," , an interventional cardiologist and chief medical officer at VitalSolution, an Ingenovis Health company, explains further. "There is some variability in time measured in milliseconds. Heart rate is controlled by the autonomic nervous system, which plays a key role in regulating your HRV. When you exercise, your heart speeds up, and when you rest, your heart slows down."Related:
Like most other health indicators, there are a lot more factors to HRV than just mere numbers—even sociological and socioeconomic factors play a role."It is influenced by age, race, sex, physical fitness, sleep, medication and health issues," , cardiologist and chief medical officer of L.A. Care Health Plan, says.Dr. Morgan notes that even caffeine intake can play a role in your HRV measurement, so putting too much stock into it may not be the best idea, but in general, there are general ranges. A normal HRV at rest for someone in their 20s is typically around 55 to 105, for example, while for someone in their 60s, it will be more like 25 to 45.Related:
https://www.youtube.com/shorts/avfNWUHWECQ
Influencer Lucie Fink talks about using Heart Rate Variability to track her COVID journey.
That depends on a few factors, experts agree, and it's by far not the most important metric to gauge your cardiovascular health by any means. "For most people, their HRV is stable over time," Dr. Amin tells us. "But some studies have shown a higher risk of heart events or even mortality in those with a reduced HRV."According to Dr. Serwer, a high HRV "means your body can switch efficiently between rest and stress modes which is a sign of good health." Conversely, he notes if you're sick, stressed, fatigued or if you over-exercise, your HRV may be lower.Related:
Chances are you don't have the equipment to get a fully accurate picture here. "The gold standard to measure HRV is by performing an EKG and precisely measuring the time between heartbeats," Dr. Serwer says. "Using advanced software, the HRV can be accurately calculated. This, however, isn't practical on a day-to-day basis."That said, Dr. Serwer and Dr. Morgan each note that certain apps and wearable technology (like fitness trackers or smartwatches) may be able to measure, track and store your values.Related:
Honestly, for most healthy people, the answer is probably no: While it doesn't necessarily hurt, it also doesn't reveal as much about your heart health as you think.
"HRV is a valuable metric which may lead us to identify stress, illness or overtraining earlier than waiting for apparent symptoms," Dr. Serwer notes, adding, "Like any test or vital sign, it is only helpful when you understand the limitations and the meaning of the value. We are often overwhelmed with data and sometimes don't pay attention to the apparent issues. HRV is a tool and when used appropriately, can be helpful."
People who may benefit from HRV monitoring are athletes and anyone worried about over-exerting themselves through exercise, or potentially recovering from an illness, and even then, your doctor will be able to make much more sense of it than most of us laypeople can.
"Monitoring HRV can offer a window into how your body is responding to stress, illness or physical overexertion," Dr. Morgan advises. "It's not all-encompassing, but it's a peek into the performance of your autonomic nervous system. Knowing this information and sharing it with your physician can help you make more informed decisions about your health and wellness."
Related:
For one, it's just not that useful, Dr. Amin says. "In general, I wouldn't suggest leaning too heavily on this measurement," he explains. "Generally, it would be best to focus on tracking more traditional markers of increased heart risk, including blood pressure, cholesterol and diabetes control."
Dr. Morgan notes that it's easy for people to get too obsessive over their heart rate variability when it can change for purely benign reasons.
"The main downside is over-interpreting the data and, frankly, worrying too much about it," she says. "HRV can fluctuate due to many factors, like sleep, hydration or even caffeine intake. It's a useful tool, but it shouldn't be the sole measure of your health. Don't worry too much if one or two readings are off—that's not good for your heart, either."
"Think of HRV as part of the bigger picture," she adds. "Trends matter more than single readings, and HRV should be viewed alongside other metrics like blood pressure, cholesterol and lifestyle habits (for example, getting eight hours of sleep per night, standing up and moving at least once per hour, taking any heart medications as prescribed, etc.). Always consult your physician if you notice concerning changes or have questions about your heart rate."
Up Next:Dr. Sameer Amin, MD
Dr. Jayne Morgan, MD
Dr. Bradley Serwer, MD
How to Use Heart Rate Variability Data In Your Training, HSS
Cardiologists Are Begging People To Stop 'Leaning Too Heavily' on This One Daily Metric first appeared on Parade on Jun 19, 2025
This story was originally reported by Parade on Jun 19, 2025, where it first appeared.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
15 minutes ago
- Forbes
Why Smoking Is Making A Comeback — And What It Means For Your Health
Gen Z is picking up where past generations left off—with a cigarette in hand. A cigarette lit on screen once symbolized noir, danger and cool detachment — think Bogart or David Lynch. Then came the lawsuits, anti-smoking campaigns, bans and the rise of vaping. For a while, it seemed America had finally kicked the habit. But now, a smoking comeback is underway. Zendaya lights up in 'Euphoria'; Jacob Elordi does the same in 'Saltburn.' Celebrities like Dua Lipa, Charli XCX, Timothée Chalamet and Anya Taylor-Joy have been spotted puffing away, becoming modern-day "cigfluencers." In 2020, cigarette sales rose for the first time in decades — though still far below the 1981 peak of 636.5 billion. Even among teens, nicotine use is shifting from vapes back to traditional cigarettes. A recent report by Truth Initiative found that tobacco depictions in top films have increased for the first time since tracking began in 2002. So what can we do? From Trend to Relapse We've been here before. In the early 20th century, cigarette smoking was glamorized in Hollywood, normalized by doctors and deeply embedded in American life. By the 1960s, nearly half of U.S. adults smoked. Then came the fallout: emphysema, heart disease, stroke, lung cancer. The medical evidence caught up with the image. Public health campaigns, warning labels, advertising bans and billions in legal settlements helped turn the tide. Not to mention, the astronomical price for a pack of cigarettes and the fact that there's no longer any places to smoke in public. The 2020 Surgeon General's report marked a historic milestone: adult cigarette smoking in the U.S. had fallen to just 14% — the lowest rate ever recorded. It was one of the greatest public health wins of the modern era. But smoking never truly disappeared. It shape-shifted. First into cigars and hookahs, then into sleek USB-like vape devices. Vaping was marketed as a safer alternative — a harm-reduction strategy. But the reality is more complicated. Juul didn't kill the cigarette. It trained a new generation to inhale nicotine. Now, we're seeing a strange reversal: from vape to smoke. From digital detox to vintage, Instagrammable vice. And once again, public health is playing catch-up to pop culture. A Healthcare Advisor's Take: Why This Matters Now In my work advising families, executives and individuals navigating complex health decisions, I've learned one truth: the greatest threats aren't the ones making headlines. They're the silent resurgences — the risks we assumed were relegated to history. Like measles. For over 20 years, we nearly eradicated it. Vaccines turned a once-common childhood illness into a relic. But now, declining vaccination rates and global travel have breathed life back into this preventable disease. Outbreaks are flaring in communities we thought were protected. Same goes for whooping cough. The resurgence of smoking may look like an edgy accessory for Gen Z. But it has real consequences, especially for anyone with a family history of heart or lung disease. What makes this moment so dangerous is the normalization. When something taboo gets rebranded as a choice — even a form of rebellion — it catches many with their guard down. People start saying things like: 'I'm just a social smoker.' 'At least it's not vaping.' 'I don't inhale.' These are the same rationalizations we heard in the 1980s. We already know where they lead. Why the Anti-Smoking Playbook of the '90s Worked — and Why It's Not Enough Now Remember those visceral commercials from the Truth Initiative? Or the public testimonies from people with tracheostomies begging kids not to smoke? Those campaigns worked because they made the consequences impossible to ignore. They also had something else: funding, legislation and social momentum. Today, the cultural winds are different. Social media algorithms reward aesthetics, not public health. TikTok doesn't run public service announcements. And with vaping muddying the waters, many young people don't even understand what they're inhaling — or how much. Legislating Against the Cigarette Comeback Even as smoking regains cultural cachet, some states are pushing back with unprecedented measures. Nevada could soon make history by becoming the first U.S. state to outlaw cigarette sales to entire generations. A proposed law (AB 279) would permanently ban sales to anyone born after 2004 — a rising age restriction designed to phase out cigarettes entirely. What's Actually in a Cigarette For all the romanticization, cigarettes remain one of the deadliest consumer products ever marketed. A single cigarette contains more than 7,000 chemicals — 69 of which are known to cause cancer. Smoking contributes to 1 in 5 deaths in the U.S. each year. And it doesn't just affect the lungs. The one question I'll guarantee your doctor will ask for your next annual checkup is this: do you smoke? Smoking increases your risk of: It also accelerates aging, damages skin elasticity and reduces stamina — none of which pairs particularly well with the image of glamour it's trying to recapture. So Why Is Gen Z Smoking? There's no one answer. But here are a few forces at play: So What Can You Do? If you're a parent, provider or simply trying to keep yourself on a healthier path, here's what I advise: In healthcare, it's easy to focus only on diagnoses and prescriptions. But as advisors, we have to stay attuned to the cultural cues — the smoke signals — that precede behavior. When the smoking comeback starts trending again, it's not just an aesthetic choice. It's a public health flare. And if we don't speak up early, we may find ourselves fighting an old war with new casualties. So the next time someone says, 'It's just one,' don't ignore it. Intervene with empathy, context, and truth. Because this time, we know better.
Health Line
20 minutes ago
- Health Line
GLP-1 Weight Loss Results Not as Effective in Everyday Life, Study Finds
Researchers report that people taking GLP-1 drugs in daily life don't lose as much weight as those in clinical trials who take the same medications. The researchers add that people using weight loss drugs don't regain weight as quickly as those in clinical trials. One possible reason for the weight loss differential is that people in the 'real world' tend to stop taking these medications sooner than people in clinical trials. People who use commonly prescribed weight loss medications don't lose as much weight as participants in clinical trials, but they also don't regain weight as quickly. That's the conclusion of a new study published on June 10 in the journal Obesity. The study authors reported that the weight loss differential was mainly due to the fact that people tend to stop using GLP-1 drugs sooner than clinical trial participants. They also tend to use lower doses of these medications. The researchers also reported that A1C blood level reductions were similar for both groups of people. The researchers noted that they will initiate further research into what other measures, such as lifestyle changes or bariatric surgery, people may have adopted after discontinuing weight loss medications such as Wegovy and Zepbound. The researchers also want to look into why people stopped using weight loss drugs before their program regimen ended. 'Our findings indicate that treatment discontinuation and use of lower maintenance dosages might reduce the likelihood of achieving clinically meaningful weight reduction in patients who initiate obesity pharmacotherapy with semaglutide or tirzepatide,' the study authors wrote. 'Our findings could inform the decisions of healthcare providers and their patients on the role of treatment discontinuation and maintenance dosage in achieving clinically meaningful weight loss,' they added. 'Real world' use of weight loss medications For their study, researchers looked at the health records of 7,881 adults with obesity or weight management issues who did not have type 2 diabetes. Those people were seen between 2021 and 2023 at the Cleveland Clinic's facilities in Ohio and Florida. Their average age was about 51 years. Nearly 80% of the subjects were white. Of those participants, 6,109 were prescribed a weight loss medication such as Wegovy with the active ingredient semaglutide. The other 1,772 were prescribed a weight loss drug, such as Zepbound, with the active ingredient tirzepatide. About 80% of those subjects were given low doses of their weekly injectable weight loss medications. Researchers reported significant differences between people using weight loss medications in phase 3 clinical trials and those taking the drugs in the 'real world.' For starters, about half of those taking either medication in daily life stopped within the first 12 months. About 51% of those using a tirzepatide drug discontinued its use in that same time period. That compares with only 17% of semaglutide users and between 14% and 16% of tirzepatide users in clinical trials who quit during the first year. In addition, the average weight reduction for semaglutide participants in daily life was nearly 8% after one year while it was 12% for people taking tirzepatide. By comparison, the average weight loss in clinical trials was nearly 15% for semaglutide subjects as well as 15% for people on low dose tirzepatide and 20% for those on a higher dose of that medication. In general, weight loss was greater in people who took weight loss medications for a longer period of time. In addition, about 54% of people who had prediabetes at the start of their treatment plan improved to healthier A1C levels after one year. Around 3% of those studied progressed to type 2 diabetes after 12 months. Weight loss is a long-term commitment Mir Ali, MD, a surgeon and bariatric surgeon as well as the medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in California, said the main takeaway from this study is that weight loss is a long-term commitment. Ali wasn't involved in the new study. 'The long-term use of medications is more effective than short-term use,' Ali told Healthline. 'The study confirms that obesity is a chronic condition like diabetes or hypertension.' Sarah Kim, MD, a professor of medicine at the University of California San Francisco, noted that discontinuing medication is common for people being treated for obesity and other conditions. Kim was likewise not involved in the new study. Kim added that adherence to medication schedules as well as diet and exercise programs isn't as easy in real life because people don't have the supervision and support a person gets during a clinical trial. 'Real life is different and results aren't always as spectacular as in clinical trials,' Kim told Healthline. Kim and Ali agreed that another reason people stop taking medications is that these drugs can be expensive, even if insurance is picking up part of the cost. There is also the fact that the side effects from these medications can be severe for some people. Plus, people in real life sometimes just get tired of the obligation of taking a pill or injecting themselves on a regular basis. Ali and Kim also noted that people need to realize that medications are only a tool to help them eat less. To lose weight and keep it off, a person needs to adopt lifestyle habits such as a healthy diet and regular exercise. 'The medications are not a short-term kickstart. They don't burn fat,' said Kim. 'The medications just help with the suppression of hunger.' 'The ultimate goal of the medications is to give people a tool to get them to a healthy weight,' Ali added. What to know about GLP-1 drug for weight loss Glucagon-like peptide-1 receptor agonists (GLP-1s) work by mimicking a hormone in the body that helps regulate blood sugar levels and reduces hunger pangs. One class of the newer GLP-1 medications uses the active ingredient semaglutide. They are sold under different brand names. Ozempic and Rybelsus have been approved to treat type 2 diabetes. Wegovy is approved for use in weight management. Semaglutide drugs are available as both oral tablets and injections. The other newer group uses the active ingredient tirzepatide. Mounjaro is approved to treat type 2 diabetes. Zepbound is approved for use in weight management. These medications are available only as injections. Previous studies have highlighted the effectiveness of these drugs on helping people lose weight. Past research has also indicated that these weight loss drugs can help lower a person's risk of cancer as well as provide benefits to heart health and brain health. Experts say the medications have proven to be effective and their use is likely to increase. 'This is a massive market and it's not going to go away,' Ali said. 'These medications are going to continue to be a big part of weight loss programs.'
Medscape
20 minutes ago
- Medscape
Europe Recommends Stem Cell Therapy for Blood Cancers
At its June 2025 meeting, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) gave a recommendation for conditional marketing authorization in the European Union for Zemcelpro (dorocubicel/allogeneic umbilical cord-derived CD34- cells non-expanded, Cordex Biologics International Limited) to treat adults with hematologic malignancies. A conditional marketing authorization is granted to a medicinal product that fulfils an unmet medical need when the benefit to public health of immediate availability outweighs the risk inherent in the fact that additional data are still required. Hematologic malignancies include leukemias, lymphomas, myelodysplastic syndrome, and myelomas. The only potential curative treatment option for several of these cancers is allogeneic hematopoietic stem cell transplantation (allo-HSCT). This type of transplant involves using donated stem cells to replace the recipient's bone marrow cells to form new bone marrow that produces healthy blood cells. Zemcelpro can be used in patients requiring an allo-HSCT following myeloablative conditioning — chemotherapy and/or radiotherapy — for whom no other type of suitable donor cells is available, the agency said. Novel Cell Therapy Zemcelpro is a novel cell therapy containing expanded CD34+ cells (dorocubicel) and unexpanded CD34- cells, each derived from the same cord blood unit. By increasing the number of cells, Zemcelpro makes the stem cells from a small cord blood unit more effective. The benefit of Zemcelpro is its ability to induce neutrophil and platelet engraftment, as observed in two single-arm, open-label, phase 2 clinical studies. The decision by the CHMP was largely based on a pooled analysis of these studies, which included 25 patients. In total, 84% of patients achieved neutrophil engraftment within a median time of 20 days, and 68% of patients achieved platelet engraftment within a median time of 40 days. In its overall assessment of the available data, the Committee for Advanced Therapies (CAT), EMA's expert committee for cell- and gene-based medicines, found that the benefits of Zemcelpro outweighed the possible risks in patients with hematologic malignancies requiring allo-HSCT for whom no matched donor cells were available. Further Study Results Requested Zemcelpro will be available as a ≥ 0.23 x 106 viable CD34+ cells/mL / ≥ 0.53 x 106 viable CD3+ cells/mL dispersion for infusion. The most common side effects with the treatment include lymphopenia, infections, anemia, neutropenia, thrombocytopenia, leukopenia, hypogammaglobulinemia, febrile neutropenia, hypertension, engraftment syndrome, pneumonia, and graft-vs-host disease (GvHD). Zemcelpro was supported through EMA's Priority Medicines (PRIME) scheme, which provides early and enhanced scientific and regulatory support to medicines that have a particular potential to address patients' unmet medical needs. To confirm the safety and efficacy of the treatment, the company has been requested to submit long-term follow-up results of the single-arm studies, and conduct a randomized controlled study as well as a study based on a patient registry.
